Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells

International Journal of Cancer

Volumn 112, Issue 3, 2004, Pages 492-501

  Marches, Radu ^a   Uhr, Jonathan W ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

G1 arrest; HER2; p27kip1; Receptor internalization

Indexed keywords

AMINE CHLOROQUINE; ANTINEOPLASTIC AGENT; CELL SURFACE RECEPTOR; CHLOROQUINE; CYCLIN DEPENDENT KINASE 2; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P27; PROTEIN SERINE THREONINE KINASE; TRASTUZUMAB; UNCLASSIFIED DRUG; AKT1 PROTEIN, HUMAN; ANTIMALARIAL AGENT; CDK2 PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MONOCLONAL ANTIBODY; ONCOPROTEIN; PROTEIN KINASE B; TUMOR SUPPRESSOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CELL MEMBRANE; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; DRUG EFFECT; DRUG EXPOSURE; DRUG POTENTIATION; ENDOCYTOSIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LYSOSOME; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; REACTION TIME; UPREGULATION; BREAST TUMOR; CELL CULTURE; DRUG ANTAGONISM; FEMALE; GENE EXPRESSION REGULATION; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTIMALARIALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CDC2-CDC28 KINASES; CELL CYCLE PROTEINS; CELL MEMBRANE; CHLOROQUINE; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DRUG SYNERGISM; ENDOCYTOSIS; FEMALE; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 6344270303     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20378     Document Type: Article

References (79)

1. Groenen LC, Nice EC, Burgess AW. Structurefunction relationships for the EGF/TGF-β family of mitogens. Growth Factors 1995;11:235-57.
2. Goldman R, Levy RB, Peles E, Yarden Y. Heterodimerization of the erbE-1 and erbE-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry 1990;29:11024-8.
3. neu protein and EGF receptor modulates EGF receptor function. Cell 1990;61:1339-47.
4. Plowman GD, Green JM, Culouscou JM, Carlton GW, Rothwell VM, Buckley S. Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature 1993;66:473-5.
5. Riese DJ, van Raaij TM, Plowman GD, Andrews GC, Stern DF. The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol 1995;15:5770-6.
6. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996;15:2452-67.
7. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-55.
8. Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y. ErbB2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 1996;15:254-64.
9. Lenferink AE, Pinkas-Kramarski R, van de Poll ML, van Vugt MJ, Klapper LN, Tzahar E, Waterman H, Sela M, van Zoelen EJ, Yarden Y. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 1998;17:3385-97.
10. Worthylake R, Opresko LK, Wiley HS. ErbB-2 Amplification inhibits downregulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 1999;274:8865-74.
11. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
12. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
13. Zhou D, Battifora H, Yokata J, Yamamoto I, Cline MI. Association of multiple copies of the c-erbB-2 oncogene with the spread of breast cancer. Cancer Res 1987;47:6123-5.
14. Borresen AL, Ottestad L, Gaustad A, Anderson TI, Heikkila R, Jahnsen T, Tveit KM, Nesland JM. Amplification and protein over-expression of the neu/HER-2/c-erB-2 proto-oncogene in human breast carcinomas: relationship to loss of gene sequence on chromosome 17, family history, and prognosis. Br J Cancer 1990;62:585-90.
15. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985;229:974-6.
16. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-91.
17. neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990;50:5184-7.
18. Park JB, Rhim JS, Park SC, Kimm SW, Kraus MH. Amplification, overexpression, and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomas. Cancer Res 1989;49:6605-9.
19. Varley JM, Swallow JE, Braminar WJ, Whittaker JL, Walker RA. Alterations to either c-erB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1987;1:423-30.
20. Lacroix H, Iglehart JD, Skinner MA, Kraus MH. Overexpression of erbB-2 or EGF-receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastasis. Oncogene 1989;4:145-51.
21. Jardines L, Weiss M, Fowble B, Greene M. neu (c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology 1993;61:268-82.
22. Peles E, Yarden Y. Neu and its ligands: from an oncogene to neural factors. Bioessays 1993;15:815-24.
23. Hynes NE, Stern DF. The biology of ErbB2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994;1198:165-84.
24. Kip1-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 2000;20:3210-23.
25. Kip1 protein: prognostic implications in primary breast cancer. Nature Med 1997;3:227-30.
26. Drebin JA, Link VC, Weinberg RA, Greene MI. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci USA 1986;83:9129-33.
27. Fendly BM, Kotts C, Vetterlein D, Lewis GD, Winget M, Carver ME, Watson SR, Sarup J, Saks S, Ullrich A. Shepard HM. The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer. J Biol Response Mod 1990;9:449-55.
28. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989;9:1165-72.
29. Stancovski I, Hurwitz E, Leitner O, Ullrich A, Yarden Y, Sela M. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ErbB2 receptor on tumor growth. Proc Natl Acad Sci USA 1991;88:8691-5.
30. Harwerth IM, Wels W, Schlegel J, Muller M, Hynes NE. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br J Cancer 1993;68:1140-5.
31. Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 1985;41:697-706.
32. van Leeuwen F, van de Vijver MJ, Lomans J, van Deemter L, Jenster G, Akiyama T, Yamamoto T, Nusse R. Mutation of the human neu protein facilitates down-modulation by monoclonal antibodies. Oncogene 1990;5:497-503.
33. HER2 and growth inhibition of cells with HER2/NEU gene amplification. Int J Cancer 1991;47:933-7.
34. Hurwitz E, Stancovski I, Sela M, Yarden Y. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc Natl Acad Sci USA 1995;92:3353-7.
35. De Santes K, Slamon D, Anderson SK, Shepard M, Fendly B, Maneval D, Press O. Radiolabeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res 1992;52:1916-23.
36. Lotti LV, Di Lazzaro C, Zompetta C, Frati L, Torrisi MR. Surface distribution and internalization of erbB-2 proteins. Exp Cell Res 1992;202:274-80.
37. Beerli RR, Wels W, Hynes NE. Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J Biol Chem 1994;269:23931-6.
38. Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990;50:1550-8.
39. HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992;89:4285-9.
40. HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-over-expressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-71.
41. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-44.
42. HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul 1991;1:72-82.
43. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox J. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999;26:60-70.
44. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-31.
45. Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998;17:2235-49.
46. Brockhoff G, Heiss P, Schlegel J, Hofstaedter F, Knuechel R. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells. Cytometry 2001;44:338-48.
47. Lane HA, Motoyama AB, Beuvink I, Hynes NE. Modulation of p27-Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. Ann Oncol 2001;12(Suppl 1):21-2.
48. Kip1 and cyclin D1 through multiple signaling pathways. Cancer Res 2001;61:6583-91.
49. KIP1 independent of MAPK activity. J Biol Chem 2000;275:6987-95.
50. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996;15:6541-51.
51. Liu W, Li J, Roth RA. Heregulin regulation of Akt/protein kinase B in breast cancer cells. Biochem Biophys Res Commun 1999;261:897-903.
52. Cdc2 kinase. Mol Cell 1998;2:581-91.
53. 1-phase progression. Genes Dev 1999;13:1501-12.
54. Flanagan JG, Leder P. neu protooncogene fused to an immunoglobulin heavy chain gene requires immunoglobulin light chain for cell surface expression and oncogenic transformation. Proc Natl Acad Sci USA 1988;85:8057-61.
55. Sorkin A, Di Fiore PP, Carpenter G. The carboxyl terminus of epidermal growth factor receptor/erbB-2 chimerae internalization is impaired. Oncogene 1993;8:3021-8.
56. Kasprzyk PG, Song SU, Di Fiore PP, King CR. Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res 1992;52:2771-6.
57. Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL, Vitetta ES. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res 2002;8:1720-30.
58. Waterman H, Sabanai I, Geiger B, Yarden Y. Alternative intracellular routing of ErbB receptors may determine signaling potency. J Biol Chem 1998;273:13819-27.
59. Sibilia M, Fleischmann A, Behrens A, Stingl L, Carroll J, Watt FM, Schlessinger J, Wagner EF. The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development. Cell 2002;102:211-20.
60. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001;61:7184-8.
61. 1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage. Oncogene 1998;16:3461-9.
62. Waldman T, Zhang Y, Dillehay L, Yu J, Kinzler K, Vogelstein B, Williams J. Cell-cycle arrest versus cell death in cancer therapy. Nat Med 1997;3:1034-6.
63. Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis. Oncogene 1999;18:1131-8.
64. waf1 initiated by membrane IgM engagement increases survival of B lymphoma cells. Proc Natl Acad Sci USA 1999;96:8711-5.
65. WAF1/CIP1 inhibits initiator caspase cleavage by TRAIL death receptor DR4. Biochem Biophys Res Commun 2000;269:179-90.
66. WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis. Cancer Res 2000;60:679-84.
67. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM. Differential responses of human tumor cell lines to anti-p185 HER2 monoclonal antibodies. Cancer Immunol Immunother 1993;37:255-63.
68. Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, O'Reilly MS, Hong WK, Fidler U, Putnam JB, Herbst RS. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 2004;10:136-43.
69. Brandt BH, Roetger A, Dittmar T, Nikolai G, Seeling M, Merschjann A, Nofer JR, Dehmer-Möller G, Junker R, Assmann G, Zaenker KS. c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells. FASEB J 1999;13:1939-49.
70. Wang Z, Zhang L, Yeung TK, Chen X. Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation. Mol Biol Cell 1999;10:1621-36.
71. Ye D, Mendelsohn J, Fan Z. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 1999;18:731-8.
72. Hahn FE. Chloroquine (Resochin). In: Corcoran JW, Hahn FE, eds. Antibiotics III: mechanism of action of antimicrobial and antitumor agents. Berlin: Springer-Verlag, 1974. 58-78.
73. Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 1987;34:155-66.
74. Howle JA, Gale GR. Cis-dichlorodiammineplatinum (II). Persistent and selective inhibition of deoxyribonucleic acid synthesis in vivo. Biochem Pharmacol 1970;19:2757-62.
75. Tao GZ, Rott LS, Lowe AW, Omary MB. Hyposmotic stress induces cell growth arrest via proteasome activation and cyclin/cyclin-dependent kinase degradation. J Biol Chem 2002;277:19295-303.
76. Wells A, Welsh JB, Lazar CS, Wiley HS, Gill GN, Rosenfeld MG. Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. Science 1990;247:962-4.
77. Reddy CC, Niyogi SK, Wells A, Wiley HS, Lauffenburger DA. Engineering epidermal growth factor for enhanced mitogenic potency. Nat Biotechnol 1996;14:1696-9.
78. Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE, Madshus IH. Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J Cell Biol 2002;156:843-54.
79. Klapper LN, Waterman H, Sela M, Yarden Y. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cb1 and enhancing Ubiquitination of HER-2. Cancer Res 2000;60:3384-8.